10-Q: Relay Therapeutics Narrows Loss, Extends Cash Runway to 2029

Relay Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D and G&A expenses, and extended its cash runway into 2029, despite the termination of its Genentech collaboration.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $147.4 million from $173.6 million in the prior year period.
• Research and development expenses decreased by $36.7 million to $137.7 million for the six months ended June 30, 2025, primarily due to strategic streamlining and cost avoidance on lirafugratinib development.
• General and administrative expenses decreased by $7.6 million to $32.4 million for the six months ended June 30, 2025, mainly due to lower stock compensation and employee costs.
• Cash, cash equivalents, and investments totaled $656.8 million as of June 30, 2025, projected to fund operations into 2029.
• The global Phase 3 ReDiscover-2 clinical trial for RLY-2608 + fulvestrant in PI3K-mutated, HR+/HER2advanced breast cancer is preparing to initiate in mid-2025.
• Updated interim clinical data for RLY-2608 + fulvestrant showed 10.3-month median progression-free survival (PFS) overall and 11.0-month median PFS in second-line patients, with a generally well-tolerated safety profile.
• The global Phase 1/2 clinical trial for RLY-2608 in PIK3CA-related overgrowth spectrum (PROS) and malformations initiated in Q1 2025 and is continuing enrollment.
• The collaboration and license agreement with Genentech, Inc. for migoprotafib (GDC-1971) was terminated effective January 7, 2025, resulting in no further milestone or other payments from Genentech.
• An exclusive global license agreement was entered into with Elevar Therapeutics, Inc. in December 2024 for lirafugratinib (RLY-4008), providing $8.4 million in upfront and material transfer payments, with eligibility for up to $495.0 million in milestones and tiered royalties.
• Approximately 70 employees were involuntarily terminated during the three months ended June 30, 2025, leading to an impairment and write-off of a $2.3 million intangible asset for assembled workforce.
• The operating lease for 46,631 square feet at 399 Binney Street was terminated, and a new lease for 12,190 square feet at 300 One Kendall Square was executed, both in June 2025.

Sentiment

Score: 7

Explanation: The company demonstrated improved financial performance with a reduced net loss and extended its cash runway significantly into 2029, which are strong positives for a clinical-stage biotech. Progress with the lead candidate RLY-2608 into Phase 3 and promising interim data, along with the Elevar licensing deal, indicate strategic execution. However, the termination of the Genentech collaboration and the ongoing accumulated deficit, coupled with the inherent risks of drug development and legal proceedings, temper the overall sentiment.

Positives

• Net loss significantly decreased to $147.4 million for the six months ended June 30, 2025, from $173.6 million in the prior year.
• Cash, cash equivalents, and investments of $656.8 million as of June 30, 2025, are expected to fund operations into 2029, providing a strong financial runway.
• RLY-2608 shows promising interim efficacy signals (10.3-month median PFS overall, 11.0-month median PFS in second-line breast cancer patients) and a well-tolerated safety profile.
• Initiation of a global Phase 3 ReDiscover-2 clinical trial for RLY-2608 in mid-2025 indicates advancement of the lead product candidate.
• The Elevar Agreement for lirafugratinib provides $8.4 million in initial payments and potential for up to $495.0 million in regulatory and commercial milestones, plus tiered royalties, diversifying revenue streams.
• Initiation of a global Phase 1/2 clinical trial for RLY-2608 in vascular malformations expands the potential indications for the lead candidate.
• Strategic streamlining of the research organization and cost avoidance on lirafugratinib development contributed to reduced R&D expenses.

Negatives

• The Genentech Agreement for migoprotafib (GDC-1971) was terminated, eliminating future milestone and other payments from this collaboration.
• Net cash used in operating activities increased to $128.5 million for the six months ended June 30, 2025, from $116.2 million in the prior year.
• An intangible asset of $2.3 million for the assembled workforce was impaired and written off due to involuntary termination of approximately 70 employees.
• The company continues to incur significant operating losses, with an accumulated deficit of $1.9 billion as of June 30, 2025.
• Interest income decreased to $14.9 million for the six months ended June 30, 2025, from $17.5 million in the prior year.

Risks

• Inability to successfully complete large-scale, pivotal clinical trials for any product candidates.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals.
• Positive data from preclinical or early clinical studies may not be predictive of later clinical study results.
• Current or future clinical trials may reveal significant adverse events not seen in earlier studies, inhibiting regulatory approval or market acceptance.
• Failure to identify viable new product candidates for clinical development could materially harm the business.
• Market opportunities for product candidates may be smaller than estimated, or approvals may be based on narrower patient populations, adversely affecting revenue and profitability.
• Substantial competition from other biopharmaceutical companies.
• Delays in obtaining required regulatory approvals for product candidates could materially impair revenue generation.
• Reliance on third parties to conduct clinical trials and manufacturing, with risks of non-compliance, missed deadlines, or performance failures.
• Need to raise substantial additional funding; inability to do so would force delays or elimination of product development programs.
• Inability to adequately protect proprietary technology or obtain/maintain patent protection, allowing competitors to develop similar products.
• Uncertainty regarding the long-term validity of the EU-U.S. Data Privacy Framework and potential for further divergence in data protection regimes.
• Risks associated with the use of new and evolving technologies, such as artificial intelligence, including intellectual property risks and increased regulatory burden.
• Potential for lawsuits alleging infringement of third-party intellectual property rights.
• Risks related to the DESRES Agreement, including the limited research term, reliance on D.E. Shaw Research's proprietary supercomputer (Anton 2), and potential disputes over intellectual property.
• Exposure to anti-kickback, fraud and abuse, and other healthcare laws and regulations once products are commercialized.
• Disruptions at government agencies (FDA, SEC) due to funding shortages or policy changes could delay regulatory review.
• Dependence on key executives and scientists; inability to attract and retain qualified personnel.
• Employees, principal investigators, CROs, and consultants may engage in misconduct or improper activities.
• Increasing use of social media platforms presents risks of non-compliance, loss of trade secrets, or reputational harm.
• Environmental, social, and governance (ESG) matters may impact business and reputation, including increased costs and potential for 'anti-ESG' sentiment.
• Reliance on single-source suppliers for active pharmaceutical ingredients (API), drug product, and starting materials.
• Potential adverse effects from natural disasters or other unplanned events on operations or third-party facilities.
• The trading price of common stock historically has been volatile, and securities class action litigation is a risk.
• Executive officers, directors, principal stockholders, and their affiliates exercise significant control over the company.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited by ownership changes.
• Changes to patent law in the United States and other jurisdictions could diminish the value of patents.
• Need to license certain intellectual property from third parties, and such licenses may not be available or on commercially reasonable terms.
• Failure to comply with obligations in collaboration or license agreements could lead to loss of rights.
• Uncertainties or disagreements around rights under intellectual property may undermine ability to partner programs.
• Changes in healthcare legislative reform measures may have a material adverse effect on business and results of operations.
• Potential reimportation of drugs from foreign countries could adversely affect operating results.

Future Outlook

Relay Therapeutics expects to continue incurring significant operating losses for the foreseeable future as it advances its lead product candidate, RLY-2608, through clinical trials, initiates trials for other candidates, and expands its early-stage programs. The company anticipates needing additional financing to support ongoing operations beyond its current cash runway into 2029, with future capital requirements dependent on clinical trial progress, regulatory approvals, and potential collaborations.

Management Comments

• We believe that, overall, while the clinical data from the ReDiscover Trial disclosed to date are preliminary, the data suggest differentiated interim efficacy signals in the specified patient population and support selective target engagement across doses and mutation types with an encouraging interim safety and tolerability profile.
• We expect to continue to incur significant expenses, including the costs of operating as a public company, and generate significant operating losses for at least the next several years.
• We believe our cash, cash equivalents, and investments of $656.8 million as of June 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements into 2029.

Industry Context

Relay Therapeutics operates in the highly competitive biopharmaceutical industry, specifically focusing on precision medicine in oncology and genetic diseases using its computational Dynamo platform. The termination of the Genentech collaboration highlights the inherent risks and evolving nature of partnerships in drug development, while the Elevar agreement demonstrates a strategy to monetize assets and focus resources. The company's advancement of RLY-2608 into Phase 3 trials positions it among peers developing targeted therapies, but it faces challenges common to clinical-stage biotechs, including substantial R&D costs, regulatory hurdles, and the need for continuous capital raises. The increasing regulatory scrutiny on AI and data privacy also reflects broader industry trends impacting drug discovery and development.

Comparison to Industry Standards

• The company's lead candidate, RLY-2608, is described as the 'first known allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3K, inhibitor in clinical development,' suggesting a potentially differentiated mechanism compared to existing or pipeline PI3K inhibitors.
• The Phase 3 ReDiscover-2 trial will compare RLY-2608 + fulvestrant against capivasertib + fulvestrant, indicating a direct competitive comparison to AstraZeneca's capivasertib (Truqap), which is approved for HR+/HER2advanced breast cancer with PIK3CA/AKT1/PTEN mutations.
• The 10.3-month median PFS overall and 11.0-month median PFS in second-line patients for RLY-2608 + fulvestrant are key efficacy metrics that will be benchmarked against approved therapies and other pipeline candidates in the PI3K-mutated breast cancer space.
• The company's reliance on its 'Dynamo platform' for drug discovery, integrating computational and experimental technologies, is a competitive approach in the biotech sector, aiming to drug previously intractable targets, similar to other AI/ML-driven drug discovery companies.
• The termination of the Genentech agreement and the new Elevar agreement reflect common industry practices of strategic portfolio management and out-licensing to optimize resource allocation and focus on core programs.

Management Changes

Corporate Governance

Legal Proceedings

• A derivative complaint (Hayes v. Borisy, et al.) was filed on December 18, 2024, in the Court of Chancery of the State of Delaware, alleging that certain directors and officers awarded excessive compensation to Board members in 2021, 2022, and 2023. Claims include breach of fiduciary duty, unjust enrichment, waste of corporate assets, and breach of fiduciary duty of disclosure. The company and defendants answered the complaint on January 24, 2025. The outcome, including potential loss or range of loss, is currently unpredictable.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; impact from RLY-2608 clinical trial success or failure; uncertainty from legal proceedings; influence of executive officers, directors, and principal stockholders.
• Employees: Approximately 70 employees involuntarily terminated in Q2 2025 as part of strategic streamlining; potential for further changes in staffing as operations expand or contract.
• Patients: Potential for new life-changing therapies from RLY-2608 in breast cancer and vascular malformations, and other pipeline candidates.
• Collaborators/Partners: Termination of Genentech agreement impacts one partner; new Elevar agreement creates a new partnership with potential for significant milestone and royalty payments.
• Creditors: Financial stability extended into 2029 due to current cash position, but future capital raises may involve debt.

Next Steps

• Initiate a global Phase 3 ReDiscover-2 clinical trial for RLY-2608 + fulvestrant in mid-2025.
• Continue enrollment in the global Phase 1/2 clinical trial for RLY-2608 in PIK3CA-related overgrowth spectrum (PROS) and malformations.
• Progress RLY-8161 (NRAS-selective inhibitor) for NRAS-mutated solid tumors.
• Progress non-inhibitory chaperone for Fabry disease.
• Continue research and development of one active early-stage discovery program.
• Seek additional financing to support continuing operations beyond the current cash runway into 2029.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statements.
• Monitor and potentially update forward-looking statements in the future.
• Address the ongoing legal proceedings related to alleged excessive director compensation.

Key Dates

Recommendation

Relay Therapeutics shows a mixed but generally improving financial picture with a reduced net loss and a significantly extended cash runway into 2029, which is crucial for a clinical-stage biotech. The advancement of RLY-2608 into a global Phase 3 trial and promising interim data are positive catalysts. The Elevar licensing deal also provides non-dilutive funding and validates an asset. However, the termination of the Genentech collaboration, the ongoing accumulated deficit, and the inherent high risks of clinical development, regulatory approval, and potential intellectual property challenges warrant caution. The legal proceeding regarding director compensation adds a layer of uncertainty. Given the progress and extended runway, but balanced against the significant risks and lack of commercial products, a 'hold' recommendation is appropriate for investors who are comfortable with the high-risk, high-reward nature of biotech investments and are awaiting further clinical and regulatory milestones.

Keywords

Biopharmaceutical, Precision Medicine, Oncology, Genetic Disease, Clinical Stage, RLY-2608, PI3K Inhibitor, Breast Cancer, Vascular Malformations, RLY-8161, NRAS Inhibitor, Fabry Disease, Drug Discovery, Dynamo Platform, SEC Filing, 10-Q, Clinical Trials, Regulatory Approval, Biotech, Pharmaceutical, Investment, Financial Results, Cash Runway, Elevar Therapeutics, Genentech, Intellectual Property, Corporate Governance, Risk Management